RT Journal Article SR Electronic T1 Paternal Exposure to Methotrexate and Pregnancy Outcomes JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 628 OP 632 DO 10.3899/jrheum.100600 VO 38 IS 4 A1 DELPHINE BEGHIN A1 MARIE-PIERRE COURNOT A1 CATHERINE VAUZELLE A1 ELISABETH ELEFANT YR 2011 UL http://www.jrheum.org/content/38/4/628.abstract AB Objective. To assess the risk of major malformation in the case of paternal exposure to methotrexate (MTX) at the time of conception. Methods. Using prospective data of our Teratology Information Service, we analyzed outcomes of paternal MTX exposure at the time of conception or up to 3 months before conception. Results. We report on the outcomes of 42 pregnancies involving 40 men treated with MTX at the time of conception. Twenty-three men were treated for an inflammatory disease (54.8%), 9 for psoriasis (21.4%), and 8 for a malignant disease (19.0%). Weekly dosages varied between 7.5 mg and 30 mg. The pregnancies resulted in 36 live births, 3 spontaneous abortions, and 3 voluntary abortions. No congenital malformation was observed at birth. Conclusion. Based on our results and case reports in literature, paternal MTX exposure at the time of conception does not seem to raise any major concern for offspring.